We applied this DTBP platform to compare analyzed plasma with analyzed tumor tissue performed by KRAS and BRAF testing in 14 prospective colorectal cancer (CRC) patients (stages I–IV) and in 10 healthy controls. Here, KRAS is linked to colorectal cancer.